These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 26559518)

  • 21. [New hope in metastatic melanoma treatment?].
    Guillot B
    Ann Dermatol Venereol; 2012 Oct; 139(10):693-4. PubMed ID: 23122388
    [No Abstract]   [Full Text] [Related]  

  • 22. BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF(V600E) mutation.
    Young K; Minchom A; Larkin J
    Future Oncol; 2012 May; 8(5):499-507. PubMed ID: 22646765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
    Seeley AR; De Los Santos JF; Conry RM
    Melanoma Res; 2015 Jun; 25(3):246-51. PubMed ID: 25746037
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vemurafenib for melanoma metastases to the brain.
    Rochet NM; Kottschade LA; Markovic SN
    N Engl J Med; 2011 Dec; 365(25):2439-41. PubMed ID: 22188003
    [No Abstract]   [Full Text] [Related]  

  • 25. Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression.
    Romano E; Pradervand S; Paillusson A; Weber J; Harshman K; Muehlethaler K; Speiser D; Peters S; Rimoldi D; Michielin O
    Clin Cancer Res; 2013 Oct; 19(20):5749-57. PubMed ID: 23948972
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Altered Morphology and Immunohistochemical Characteristics in Metastatic Malignant Melanoma After Therapy With Vemurafenib.
    Powell MR; Sheehan DJ; Kleven DT
    Am J Dermatopathol; 2016 Sep; 38(9):e137-9. PubMed ID: 27541173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regression of orbital and choroidal metastases from melanoma after treatment with vemurafenib.
    Ngo E; Hutchins LF; Gardner JM; Uwaydat SH
    Can J Ophthalmol; 2014 Apr; 49(2):e49-52. PubMed ID: 24767240
    [No Abstract]   [Full Text] [Related]  

  • 28. S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma.
    Abusaif S; Jradi Z; Held L; Pflugfelder A; Weide B; Meier F; Garbe C; Eigentler TK
    Melanoma Res; 2013 Oct; 23(5):396-401. PubMed ID: 23907232
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Case series: indoor-photosensitivity caused by fluorescent lamps in patients treated with vemurafenib for metastatic melanoma.
    Boudewijns S; Gerritsen WR; Koornstra RH
    BMC Cancer; 2014 Dec; 14():967. PubMed ID: 25515496
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor.
    Patrawala S; Puzanov I
    Future Oncol; 2012 May; 8(5):509-23. PubMed ID: 22646766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of a novel complex BRAF mutation associated with major clinical response to vemurafenib in a patient with metastatic melanoma.
    Busser B; Leccia MT; Gras-Combe G; Bricault I; Templier I; Claeys A; Richard MJ; de Fraipont F; Charles J
    JAMA Dermatol; 2013 Dec; 149(12):1403-6. PubMed ID: 24108467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic markers and tumour growth kinetics in melanoma patients progressing on vemurafenib.
    Seifert H; Fisher R; Martin-Liberal J; Edmonds K; Hughes P; Khabra K; Gore M; Larkin J
    Melanoma Res; 2016 Apr; 26(2):138-44. PubMed ID: 26684061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fanconi syndrome induced by vemurafenib: a new renal adverse event.
    Denis D; Franck N; Fichel F; Levi C; Dupin N
    JAMA Dermatol; 2015 Apr; 151(4):453-4. PubMed ID: 25494458
    [No Abstract]   [Full Text] [Related]  

  • 34. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
    Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
    Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Response rate to vemurafenib in patients with B-RAF-positive melanoma brain metastases: a retrospective review.
    Dzienis MR; Atkinson VG
    Melanoma Res; 2014 Aug; 24(4):349-53. PubMed ID: 24709889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vemurafenib-induced pityriasis amiantacea: a case report.
    Bilgiç Ö
    Cutan Ocul Toxicol; 2016 Dec; 35(4):329-31. PubMed ID: 26513697
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cerebrospinal fluid concentrations of vemurafenib in patients treated for brain metastatic BRAF-V600 mutated melanoma.
    Sakji-Dupré L; Le Rhun E; Templier C; Desmedt E; Blanchet B; Mortier L
    Melanoma Res; 2015 Aug; 25(4):302-5. PubMed ID: 25933211
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.
    Dummer R; Goldinger SM; Turtschi CP; Eggmann NB; Michielin O; Mitchell L; Veronese L; Hilfiker PR; Felderer L; Rinderknecht JD
    Eur J Cancer; 2014 Feb; 50(3):611-21. PubMed ID: 24295639
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vemurafenib for the treatment of melanoma.
    Jordan EJ; Kelly CM
    Expert Opin Pharmacother; 2012 Dec; 13(17):2533-43. PubMed ID: 23094782
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Latest developments in the treatment of melanoma: 'a penicillin moment for cancer'?
    Retsas S
    J R Soc Med; 2011 Jun; 104(6):269-72. PubMed ID: 21659402
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.